. Author manuscript; available in PMC: 2011 Apr 1.

Published in final edited form as: Genet Med. 2010 Apr;12(4 Suppl):S15–S38. doi: 10.1097/GIM.0b013e3181d5a67b

TABLE 3.

COST EFFECTIVENESS STUDIES COMPARING CHEMOPREVENTION TO SURVEILLANCE ALONG

Study	Context	Results (Cost per QALY)
Grann (2000)⁹⁸	Positive BRCA test	30 year old women = $990
		40 year old women = $1,800
		50 year old women = $3,600
Hershman (2002)⁹⁹	Two-or-more first-degree relatives diagnosed with breast cancer	30 year-old women = $45,000
		50 year-old women = $89,000
		60 year-old women = $140,000
Eckermann (2003)¹⁰⁰	Hypothetical cohort of healthy women at high risk of breast cancer	5 yrs of tamoxifen / 5 yrs of benefit = $32,000
		5 yrs of tamoxifen / 10 yrs of benefit = $16,000
		5 yrs of tamoxifen / no reduced incidence at 10 yrs = $170,000

Notes: QALY = “Quality Adjusted Life Year”